Alzheimer's disease (AD) is the leading cause of dementia, presenting a significant unmet medical need worldwide. The pathogenesis of AD involves various pathophysiological events, including the accumulation of amyloid and tau, neuro-inflammation, and ne
de Fatima, Design of New Drugs for the Treatment of Alzheimer's Disease Based on Tacrine Structure. Curr. Drug Targets, 2013. 14: 378-397.de Aquino, R.A.N., Modolo, L.V., Alves, R.B., de Fatima, A. Design of new drugs for the treatment of Alzheimer's disease based on ...
Alzheimer disease (AD) accounts for 60–70% of dementia cases. Given the seriousness of the disease and continual increase in patient numbers, developing effective therapies to treat AD has become urgent. Presently, the drugs available for AD treatment, including cholinesterase inhibitors and an anta...
Alzheimer disease (AD) represents a major global medical, social, and economic burden. The World Alzheimer Report 2022 revealed that more than 55 million people have AD or related conditions worldwide, and this number is projected to reach 82 million by 2030 and 138 million by 2050 [1]. Typ...
Pharmacologic treatment of the disease generally seeks to correct the histopathology, the biochemical derangements or their effects. The only drugs labeled to date for the treatment of cognitive symptoms in patients with Alzheimer's disease are two cholinesterase inhibitors that prevent the breakdown of ...
The Food and Drug Administration approved a new Alzheimer's treatment called donanemab on Tuesday, clearing the way for the third addition to a new class of drugs aimed at slowing the brain's decline in patients facing the early stages of the disease. Branded as Kisunla by drugmaker Eli ...
根据第二段The brain science behind Alzheimer's is complex,but CT and MRI scans suggest that poisonous changes occur in the brain,including the abnormal buildup of proteins called amyloid plaques and tau tangles.(阿尔茨海默氏症背后的脑科学是复杂的,但CT和MRI扫描表明,大脑中发生了...
“If approved, the drugs are likely to be relevant only for a relatively small cohort of Alzheimer’s patients, so potential recipients will need to undergo a range of assessments before being given access to the drugs. Plus, effect sizes seen in the trials are very small and the drugs ...
Alzheimer's disease comes to affect at 10% of the greater population of 65 years and to near the 50% up 85 years. The brain lesions more characteristics are the senile plaques and neurofibrillary tangles. Actually, drugs like Tacrine have been used to replace the loss of cholinergic activity...
The first new drug for Alzheimer's disease in nearly 20 years received approval from government health officials on Monday. The decision disregarded warnings from independent advisers that the much-debated treatment hasn't been shown to help slow the brain-destroying disease. ...